Progressive Supranuclear Palsy News and Research

RSS

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

4 Nov 2024

Carbonic anhydrase inhibitors clear tau build-up in zebrafish models of tauopathies

A drug commonly used to treat glaucoma has been shown in zebrafish and mice to protect against the build-up in the brain of the protein tau, which causes various forms of dementia and is implicated in Alzheimer’s disease.

4 Nov 2024

Glaucoma medication may help prevent Alzheimer's-related tau build-up

1 Nov 2024

Scientists develop selective therapy for tau tangles

Scientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.

14 Sep 2024

Study reveals shared and unique molecular markers across multiple forms of dementia

Researchers have for the first time identified degeneration-associated "molecular markers" – observable changes in cells and their gene-regulating networks – that are shared by several forms of dementia that affect different regions of the brain.

11 Sep 2024

Major trial to test multiple drugs for progressive supranuclear palsy

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start.

3 Sep 2024

New compound shows promise in Alzheimer’s preclinical models

A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego, has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.

21 Aug 2024

NIH awards $6.9 million to prepare a potential Alzheimer's treatment for future clinical trials

A multidisciplinary team of scientists led by Carlo Ballatore, Ph.D., at University of California San Diego and Kurt Brunden, Ph.D., at the University of Pennsylvania has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.

20 Aug 2024

Protein biomarkers in spinal fluid offer promise for early progressive supranuclear palsy diagnosis

Progressive supranuclear palsy (PSP), a mysterious and deadly neurological disorder, usually goes undiagnosed until after a patient dies and an autopsy is performed.

3 Jul 2024

Blood test identifies specific pathologies in frontotemporal dementia, ALS, and PSP

In a study with 991 adults, scientists at DZNE show that the most common forms of frontotemporal dementia (FTD) as well as the neurological diseases amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP) can be recognized by blood testing.

18 Jun 2024

New treatments in sight for challenging neuropsychiatric symptoms in neurodegenerative diseases

Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.

3 Apr 2024

Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases

A spectrum of neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are due to the accumulation of abnormal, misfolded tau proteins in the brain.

3 Apr 2024

C-Path announces formation of new task force to foster drug development for Progressive Supranuclear Palsy

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform, dedicated to advancing therapeutic development for Progressive Supranuclear Palsy.

26 Mar 2024

UVA Alzheimer's study pinpoints how tau protein damages brain cells

University of Virginia Alzheimer's researchers have discovered how harmful tau proteins damage the essential operating instructions for our brain cells, a finding which could lead to new treatments.

20 Dec 2023

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Wearable devices and machine learning revolutionize Parkinson's disease monitoring

The quantitative progression of motor symptoms of Parkinson's disease (PD) over time using wearable sensor data.

11 Oct 2023

New tau PET radiotracer shows promise for early detection of Alzheimer's disease

A new tau PET radiotracer, 18F-SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer's disease in its earliest stages, according to research published in the September issue of The Journal of Nuclear Medicine.

29 Sep 2023

Decoding tauopathies: New study identifies non-coding RNA as a key player in Alzheimer's

Researchers at Washington University School of Medicine identify a key step in the development of harmful tau tangles, offering a potential target for preventing brain damage in diseases like Alzheimer's. The study highlights the role of long noncoding RNAs, particularly SNHG8, in stress granule formation and tau aggregation, opening new avenues for treatment.

22 Sep 2023

Penn Medicine researchers identify new therapeutic target for Alzheimer's disease

A gene encoding a protein linked to tau production-;tripartite motif protein 11 (TRIM11)-;was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

27 Jul 2023

Researchers explore multi-syndrome prediction of dementia syndromes

A new study explored how support vector machines (SVMs) applied to magnetic resonance imaging (MRI) data can differentiate different dementia syndromes.

16 Jan 2023